



Enhancing Quality of Life

First-in-Class Therapies Regenerating Blood Vessels







Our Mission: Enhancing healthy aging with pioneering therapies that restore vascular function.

Our Vision: We are creating a future where vascular diseases no longer limit life's potential.




Unmet Clinical Need

With increasing life expectancy, age-related diseases are on the rise, while effective treatments remain limited. A key underlying factor is **impaired blood circulation**.



Young Skin



Old Skin

Topadur's Focus Indications

Chronic Wounds



Extremity Amputations

Worldwide, every 20s a person with diabetes loses a lower limb lacking efficient therapies*.

Alopecia



Psychological burden

Alopecia is on the rise and can cause major distress and reduced quality of life.


Skin Aging



Functional Impairments


Age-related skin changes include increased fragility and delayed recovery.

Topadur's DualTOP® Technology Platform




TOP-N53 Increases Vasodilation and Angiogenesis in Mouse Wounds

Angiogenesis




Hydrogel

TOP-N53




Blood Perfusion




Phase1 Clinical Trial in Human Volunteers : A Single Application of TOP-N53 is Safe and Effective

Study Type	Randomized, double-blind (intra-individual), vehicle-controlled
Number of Centres	Single centre in Mannheim, Germany
Patients	29 healthy volunteers
Administration	Subcutaneous injection
Doses	Single doses, ascending from MRSD to MTD (0.6-9.6µg TOP-N53)
Outcome/Endpoints	No adverse events, no pain, no erythema Exploratory: increase in vascular conductance at higher doses

Vascular Conductance



Topadur's Lead Assets are at Advanced Development Stages



SR = sustained release

9

Experienced Board and Leadership Team



Dr. Reto Naef
Founder and Board President
Senior Scientific Advisor



Dr. Daniel Vasella
Board Vice President



Dr. Dominik Escher
Board Member



Silvia Scherer
Board Member



Prof. Dr. Günther Wess
Board Member



Prof. Dr. Thierry Carrel
Board Member




Cornelia Gehrig
Board Member
CFO a.i.




PD Dr. Matthias Schäfer
CEO

Series C2 Capital Deployment



Topadur's Asset Development Plan



Topadur Targets Attractive Markets ...



Market Size



Revenue Projection

Systemic Sclerosis/ Digital Ulcer

Total

\$2.9B_{p.a.}

6.4% CAGR

Therapy

> \$1B_{p.a.}

Diabetic Foot Ulcer

Therapy

\$8.2B_{p.a.}

5.9% CAGR

Therapy/Prevention

> \$1B/5B_{p.a.}

Alopecia

\$8.8B_{p.a.}

9.1% CAGR

> \$2B_{p.a.}

Skin Rejuvenation

\$24B_{p.a.}

4.5% CAGR

> \$5B_{p.a.}

Summary

1. High-Value Technology and Pipeline

Innovative therapies to regenerate blood vessels in age-related diseases targeting attractive markets. Assets in advanced development stage with accelerated market access for digital ulcer therapy. Two revolutionary preclinical projects in obesity and targeted tumor therapies.

2. Robust Patent Portfolio

Long-lasting innovation life span built on composition of matter and formulation patents lasting into the 2040s. Market exclusivity granted in Europe and the USA (Orphan designation).

3. High Management Expertise

Decades of proven leadership in pharmaceutical R&D, business development and commercialization.

4. IPO target 2027

Improving the way people age

Contact for investment opportunities:

Topadur Pharma AG
Grabenstrasse 11a
8952 Schlieren, Switzerland

+41 44 755 44 66
matthias.schaefer@topadur.com



This presentation is private and confidential, has been furnished to you solely for your information and may not be reproduced, redistributed or disclosed in any way, in whole or in part, directly or indirectly, in or into the United States or the United Kingdom, Canada, Australia, Japan, any Member State of the European Economic Area or any other jurisdiction where such distribution or release would be unlawful, or to any other person without the prior written consent of Topadur AG (the "Company"). The maintenance of the absolute secrecy of the information contained in this presentation is of paramount importance to the Company, its business and financial prospects. This presentation does neither constitute an offer or invitation to buy or to subscribe to securities of the Company nor a prospectus within the meaning of the applicable Swiss law. Investors should make their decision to exercise rights, to buy or to subscribe to any securities of the Company solely based on an offering and listing prospectus which would be published in connection with an offering of securities of the Company. Investors are furthermore advised to consult their bank or financial adviser. This presentation may contain specific forward-looking statements, e.g., statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the Company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments. Market data and other statistical information used throughout this presentation are based on industry publications and surveys, reports by market research firms or other published independent sources. Some data is based on the Company's internal estimates which are derived from the review of internal surveys, as well as the independent sources. The Company's estimates involve risks and uncertainties and are subject to change based on various factors. Although the Company believes these sources are reliable, it has not independently verified the information and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions expressed herein. The Company and its subsidiaries, managers, directors, officers, employees, agents or advisors shall have no liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information and opinions contained in this presentation do not purport to be comprehensive, are provided as at the date of this presentation and are subject to change without notice.

THIS PRESENTATION shall not be RELEASED, reproduced, redistributed or disclosed in any way, in whole or in part, directly or indirectly IN THE USA, IN THE UNITED KINGDOM, IN AUSTRALIA, CANADA, JAPAN, ANY MEMBER STATE OF THE EEA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, REPRODUCTION, REDISTRIBUTION OR DISCLOSURE WOULD BE UNLAWFUL AND SHOULD NOT BE RELEASED OR DISTRIBUTED TO U.S. PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, CANADA, JAPAN, MEMBER STATES OF THE EEA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION WOULD BE UNLAWFUL AND MUST NOT BE DISTRIBUTED OR DISSEMINATED TO ONE OF THESE COUNTRIES BY PUBLICATIONS WITH A GENERAL CIRCULATION.

THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES. THE SECURITIES OF TOPADUR AG HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933 AS AMENDED AND ARE NOT BEING OFFERED IN THE UNITED STATES OR TO U.S. PERSONS. In relation to the United Kingdom this communication is not being made, and this presentation has not been approved, by an authorized person for the purposes of Section 21 of the Financial Services and Markets Act 2000. Accordingly, this presentation is not being distributed to, and must not be passed on to, the general public in the United Kingdom. Rather, the communication of this presentation is being made to, and is directed only at persons outside the United Kingdom. This presentation is only available to such persons outside the United Kingdom, and this presentation must not be acted on or relied upon by any other person. In relation to each Member State of the EEA which has implemented the Regulation (EU) 2017/1129 (the "Prospectus Regulation") (each a "Relevant Member State"), an offer to the public of shares of the Company may not be made in that Relevant Member State. An offer to the public of shares of the Company may in particular also not be made under the provisions of Article 3 of the Prospectus Regulation or the respective regulations of national regulations implementing the Prospectus Regulation. This presentation and the information contained herein does not constitute an "offer of securities to the public" within the meaning of the Prospectus Regulation. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities of the Company, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction